natgillin/translations-raw huggingface dataset:
The active substances in the medicine, lidocaine and prilocaine, are local anaesthetics that temporarily numb the contact area by reversibly blocking the transmission of signals in the nerves. 
Zdravilni učinkovini v zdravilu, lidokain in prilokain, sta lokalna anestetika, ki začasno omrtvita območje, s katerim sta v stiku, z blokiranjem prenosa živčnih signalov.
The European Medicines Agency considered that the active ingredients are a well-known local anaesthetic combination, and the use of a local spray minimises the amount of active substance absorbed and hence the risk of side effects affecting the body as a whole. 
Evropska agencija za zdravila je menila, da sta učinkovini dobro znana kombinacija lokalnih anestetikov, uporaba lokalnega razpršila pa zmanjšuje količino absorbirane učinkovine in s tem tveganje neželenih učinkov, ki vplivajo na telo kot celoto.
Senstend is a medicine containing the active substances lidocaine and prilocaine. 
Senstend je zdravilo, ki vsebuje učinkovini lidokain in prilokain.
This reduces sensitivity to stimulation, and when applied onto the head of the penis this will help to increase the time taken to ejaculate. 
Tako se zmanjša občutljivost na stimulacijo in ko se zdravilo nanese na glavico penisa pripomore k podaljšanju časa pred ejakulacijo.
What are the risks associated with Senstend? 
Kakšna tveganja so povezana z zdravilom Senstend?
Senstend must not be used in patients who are hypersensitive (allergic) to any of the ingredients of the medicine or to other local anaesthetics with a structure related to the active ingredients (amidetype local anaesthetics). 
Zdravilo Senstend se ne sme uporabljati pri bolnikih, ki so preobčutljivi za (alergični na) katero koli sestavino zdravila ali na druge lokalne anestetike, sestavljene podobno kot učinkovini (lokalni anestetiki amidnega tipa).
Doses should not be repeated more frequently than every 4 hours, and no more than three doses should be used in 24 hours. 
V 24 urah se lahko uporabi največ tri odmerke v razmiku najmanj štirih ur.
How is Senstend used? 
Kako se zdravilo Senstend uporablja?
The recommended dose is three sprays onto the head (glans) of the penis before intercourse. 
Priporočeni odmerek je tri potiske, s katerimi se prekrije glavico penisa pred spolnim odnosom.
The effectiveness of Senstend has been shown in two main studies involving 256 and 300 heterosexual adult men with premature ejaculation, respectively; both studies compared the medicine with a placebo (dummy) spray over 12 weeks. 
Učinkovitost zdravila Senstend je bila izkazana v dveh glavnih študijah, v kateri je sodelovalo 256 oziroma 300 heteroseksualnih odraslih moških s prezgodnjo ejakulacijo.
For the full list of side effects reported with Senstend, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Senstend, glejte navodilo za uporabo.
How does Senstend work? 
Kako zdravilo Senstend deluje?
In the first study, the average time to ejaculation in patients treated with Senstend was 2.6 minutes, compared with 0.8 minutes in those using placebo; in the second study, 
prejemali zdravilo Senstend, 2,6 minut, v primerjavi z 0,8 minut pri tistih, ki so prejemali placebo.
The response was sustained for at least 48 weeks; 
Odziv se je ohranjal najmanj 48 tednov;
This was switched to a full marketing authorisation on 14 July 2009. 
To je bilo 14. julija 2009 spremenjeno v običajno dovoljenje za promet.
Further information on Isentress can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Nadaljnje informacije za zdravilo Isentress so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Therefore, the effectiveness observed in adults is also expected in children. 
Zato se učinkovitost, opažena pri odraslih, pričakuje tudi pri otrocih;
Equivalent doses of these different forms do not all produce the same levels of raltegravir in the body, so they must not be used interchangeably. 
Enakovredni odmerki teh različnih oblik zdravila ne proizvedejo vsi enakih ravni raltegravirja v telesu, zato jih ne smemo uporabljati izmenjaje.
What measures are being taken to ensure the safe and effective use of Isentress? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Isentress?
Side effects in children were comparable to those in adults. 
Neželeni učinki pri otrocih so bili primerljivi s tistimi pri odraslih.
This study looked at viral loads after 24 and 48 weeks. 
V tej študiji so proučevali virusno breme po 24 oziroma 48 tednih.
The European Medicines Agency therefore decided that Isentress's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Isentress večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
• Additional supportive studies established doses that provide similar effective levels of Isentress in newborn infants as in young children. 
• Dodatne podporne študije so določile doze, s katerimi se dosežejo podobne učinkovite ravni zdravila Isentress pri novorojenčkih in majhnih otrocih.
Isentress has been studied in six main studies. 
Zdravilo Isentress so proučevali v šestih glavnih študijah:
Isentress received a conditional marketing authorisation valid throughout the European Union for Isentress on 20 December 2007. 
Promet z zdravilom Isentress je bil pogojno dovoljen po vsej Evropski uniji od 20. decembra 2007.
As for all medicines, data on the use of Isentress are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Isentress stalno spremljajo.
• A fourth study in 802 patients who had not taken HIV treatment before showed that giving Isentress as a single dose of 1,200 mg once daily was as effective as giving 400 mg twice daily. 
• v četrti študiji pri 802 bolnikih, ki predhodno niso prejemali zdravljenja za okužbo z virusom HIV, so dokazali, da je dajanje zdravila Isentress kot enojnega odmerka 1 200 mg enkrat dnevno tako učinkovito kot dajanje odmerka 400 mg dvakrat dnevno.
Side effects reported with Isentress are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Isentress, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
When the enzyme is blocked, the virus cannot reproduce normally, slowing down the spread of infection. 
Ko je encim zavrt, se virus ne more več normalno razmnoževati, kar zmanjša hitrost širjenja okužbe.
Isentress was as effective as efavirenz. 
Zdravilo Isentress je bilo tako učinkovito kot efavirenz.
Why is Isentress authorised in the EU? 
Zakaj je bilo zdravilo Isentress odobreno v EU?
It blocks an enzyme called integrase, which is involved in a step in the reproduction of HIV. 
Zavira encim, imenovan integraza, ki sodeluje na stopnji razmnoževanja virusa HIV.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Isentress have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Isentress upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
The granules are to make a mixture for babies and children to drink, the chewable tablets are for bigger children, and the 400- and 600-mg tablets are for different dose regimens in older children and adults, as recommended by the doctor. 
Zrnca se zmešajo v mešanico, ki jo popijejo dojenčki in otroci, žvečljive tablete so za večje otroke, 400- in 600miligramske tablete pa so za različne režime odmerjanja pri starejših otrocih in odraslih po navodilu zdravnika.
The medicine is available as tablets to be swallowed (400 and 600 mg), chewable tablets (25 and 100 mg) and sachets containing granules for an oral suspension (each sachet containing 100 mg). 
Zdravilo je na voljo v obliki tablet, ki se pogoltnejo (400 in 600 mg), žvečljivih tablet (25 in 100 mg) ter vrečk z zrnci za peroralno suspenzijo (posamezna vrečka vsebuje mg).
There have also been uncommon reports of rhabdomyolysis (breakdown of muscle fibres). 
Obstajajo tudi občasna poročila o rabdomiolizi (razgradnji mišičnih vlaken).
For more information about using Isentress see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Isentress glejte navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
An overview of Isentress and why it is authorised in the EU 
Pregled zdravila Isentress in zakaj je odobreno v EU
The most common serious side effects are immune reconstitution syndrome (symptoms of infection caused by a recovering immune system) and rash. 
Najpogostejša resna neželena učinka zdravila sta vnetni sindrom imunske obnove (simptomi vnetja, povzročeni z obnavljanjem imunskega sistema) in izpuščaj.
The study showed that Isentress, given as tablets to be swallowed or chewable tablets, was safe in children and levels of the medicine obtained in the blood in children were similar to those obtained in adults. 
Študija je pokazala, da je zdravilo Isentress, dajano v obliki tablet, ki jih je treba pogoltniti ali žvečiti, varno za otroke, dosežene ravni zdravila v krvi pri njih pa so bile podobne tistim, ki so bile dosežene pri odraslih.
Isentress, taken in combination with other HIV medicines, reduces the amount of HIV in the blood and keeps it at a low level. 
Zdravilo Isentress v kombinaciji z drugimi zdravili proti virusu HIV zniža količino virusa HIV v krvi in jo ohranja na nizki ravni.
• Two studies involved a total of 699 ‘treatment-experienced' patients who were already receiving treatment for HIV infection that was not working. 
• v dveh študijah je sodelovalo 699 že zdravljenih bolnikov, ki so prejemali zdravljenje za okužbo z virusom HIV, ki ni bilo uspešno.
What is Isentress and what is it used for? 
Kaj je zdravilo Isentress in za kaj se uporablja?
The most common side effects with Isentress (seen in between 1 and 10 patients in 100) are headache, abdominal pain (stomach ache) and nausea (feeling sick). 
Najpogostejši neželeni učinki zdravila Isentress (opaženi pri 1 do 10 bolnikih od 100) so glavobol, bolečine v trebuhu in navzeja (slabost).
• Isentress has also been studied in a fifth study involving 126 HIV-1 infected children between 2 and 18 years whose existing treatment for HIV infection was not working. 
• zdravilo Isentress so proučevali tudi v peti študiji pri 126 otrocih, okuženih z virusom HIV-1 in starih od 2 do 18 let, pri katerih je bilo tedanje protivirusno zdravljenje neuspešno.
• A third study involved 566 patients who had not taken HIV treatment before and compared Isentress with efavirenz (another HIV medicine). 
• v tretji študiji je sodelovalo 566 bolnikov, ki predhodno niso prejemali protivirusnega zdravljenja; v njej so primerjali zdravilo Isentress z efavirenzem (drugim zdravilom za zdravljenje okužbe z virusom HIV).
What benefits of Isentress have been shown in studies? 
Kakšne koristi je zdravilo Isentress izkazalo v študijah?
• A sixth study included 26 children aged 4 weeks to 2 years who were given Isentress oral granules made into a suspension. 
• v šesti študiji je sodelovalo 26 otrok, starih od 4 tednov do 2 let, ki so prejemali zrnca zdravila Isentress za peroralno uporabo v suspenziji.
Isentress does not cure HIV infection or AIDS, but it may hold off the damage to the immune system and the development of infections and diseases associated with AIDS. 
Zdravilo Isentress ne ozdravi okužbe z virusom HIV ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter prepreči razvoj okužb in bolezni, povezanih z aidsom.
The active substance in Isentress, raltegravir, is an integrase inhibitor. 
Zdravilna učinkovina v zdravilu Isentress, raltegravir, je zaviralec integraze.
The studies compared Isentress with placebo (a dummy treatment), which were added to ‘optimised background therapy' (a combination of other HIV medicines chosen for each patient as it had the best chances of reducing the levels of HIV in the blood). 
V študijah so primerjali zdravilo Isentress s placebom (zdravilom brez zdravilne učinkovine), ki so ju dodali optimiziranemu osnovnemu zdravljenju (kombinaciji drugih protivirusnih zdravil, izbranih za vsakega posameznega bolnika glede na to, da je imel z njo bolnik najboljše možnosti zmanjšanja ravni virusa HIV v krvi).
The main measure of effectiveness was the number of patients who had ‘undetectable' viral loads (below 50 copies per millilitre of blood) after 48 weeks. 
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih je bilo po 48 tednih virusno breme „nezaznavno“ (manj kot 50 kopij na mililiter krvi).
Patients also received the medicine Truvada (emtricitabine with tenofovir disoproxil). 
Bolniki so prejemali tudi zdravilo Truvada (emtricitabin s tenofovirdizoproksilom).
Isentress is an HIV medicine that is used in combination with other HIV medicines to treat patients who are infected with human immunodeficiency virus (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). 
Zdravilo Isentress se uporablja v kombinaciji z drugimi zdravili za zdravljenje okužbe z virusom HIV pri bolnikih, ki so okuženi z virusom humane imunske pomanjkljivosti (HIV-1), ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
All of the patients also took tenofovir and emtricitabine (other HIV medicines). 
Vsi bolniki so prejemali tudi tenofovir in emtricitabin (drugi zdravili za zdravljenje okužbe z virusom HIV).
Other information about Isentress: 
Druge informacije o zdravilu Isentress
What are the risks associated with Isentress? 
Kakšna tveganja so povezana z zdravilom Isentress?
For the full list of side effects and restrictions with Isentress, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Isentress glejte navodilo za uporabo.
The main measure of effectiveness was the reduction in the levels of HIV in the blood (viral load) after 16 weeks; 77% of the patients who took Isentress had viral loads below 400 copies/ml after 16 weeks, compared with 42% of those who took placebo. 
Glavno merilo učinkovitosti je bilo zmanjšanje ravni virusa HIV v krvi (virusnega bremena) po 16 tednih; pri 77 % bolnikov, ki so dobili zdravilo Isentress, je bilo po 16 tednih virusno breme nižje od 400 kopij/ml v primerjavi z 42 % tistih, ki so dobili placebo.
Isentress can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of HIV infection. 
Predpisovanje in izdaja zdravila Isentress je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
Isentress treatment led to a reduction in viral load and after 48 weeks 53% of the children had viral loads below 50 copies/ml. 
Pri zdravljenju z zdravilom Isentress se je zmanjšalo virusno breme, ki je bilo po 48 tednih pri 53 % otrok nižje od 50 kopij/ml.
Isentress has been shown to be effective in helping control HIV when used with other HIV medicines. 
Zdravilo Isentress se je izkazalo za učinkovito pri nadzorovanju virusa HIV v kombinaciji z drugimi zdravili za zdravljenje tega virusa.
After 48 weeks, 89% (472 of 531) of those on the once daily dose and 88% (235 of 266) of those taking Isentress twice daily had viral loads less than 40 copies/ml; 
Po 48 tednih je bilo virusno breme pri 89 % (472 od 531) tistih, ki so prejemali odmerek enkrat dnevno, in 88 % (235 od 266) tistih, ki so jemali zdravilo Isentress dvakrat dnevno, nižje od 40 kopij/ml;
After 48 weeks, 86% of the patients taking Isentress had viral loads below 50 copies/ml (241 out of 281), compared with 82% of those taking efavirenz (230 out of 282); 
Po 48 tednih so bila pri 86 % bolnikov (241 od 281), ki so jemali zdravilo Isentress, virusna bremena nižja od 50 kopij/ml v primerjavi z 82 % tistih, ki so jemali efavirenz (230 od 282);
How is Isentress used? 
Kako se zdravilo Isentress uporablja?
How does Isentress work? 
Kako zdravilo Isentress deluje?
Isentress contains the active substance raltegravir. 
Vsebuje zdravilno učinkovino raltegravir.
These measures should help to protect the environment. 
Ti ukrepi pomagajo varovati okolj.
Tel: +353 (0)1 4515011 Fax: +353 (0)1 4621859 
Tel.: +353 (0)1 4515011 Faks: +353 (0)1 4621859
Do not broach more than 50 times. 
Zamaška ne predrite več kot petdesetkrat.
Do not use in horses less than 6 weeks of age. 
Ne uporabljajte pri konjih, mlajših od 6 tednov.
Date of last renewal: 09/08/2016 
Datum podaljšanja dovoljenja za promet: 09/08/2016
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 13/09/2011 
DATUM PRIDOBITVE/DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 13/09/2011
Marketing authorisation holder and manufacturer responsible for batch release: Bimeda Animal Health Limited, 
Imetnik dovoljenja za promet z zdravilom in izdelovalec, odgovoren za sproščanje serij:: Bimeda Animal Health Limited
MARKETING AUTHORISATION NUMBERS EU/2/11/133/001-003 
ŠTEVILKE DOVOLJENJ ZA PROMET EU/2/11/133/001-003
For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age. 
Pri zdravljenju driske pri govedu ne uporabljajte pri živalih, mlajših od enega tedna.
The excipients listed in section 6.1 of the SPC are allowed substances for which table 1 of the annex to Commission Regulation (EU) No. 37/2010 indicates that no MRLs are required. 
Za pomožne snovi, navedene v poglavju 6.1 SPC, tabela 1 (dovoljene snovi) Priloge Uredbe Komisije (EU) št. 37/2010 določa, da navedba MRL ni potrebna.
Avoid introduction of contamination during use. 
Pazite, da med uporabo ne pride do kontaminacije.
The metabolism in horses has not been investigated. 
Presnove pri konjih niso preučili.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 
Pogostnost neželenih učinkov je določena po naslednjem dogovoru:: - zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10 zdravljenih živali) - pogosti (pri več kot 1, toda manj kot 10 živali od 100 zdravljenih živali) - občasni (pri več kot 1, toda manj kot 10 živali od 1.000 zdravljenih živali) - redki (pri več kot 1, toda manj kot 10 živali od 10.000 zdravljenih živali) - zelo redki (pri manj kot 1 živali od 10.000 zdravljenih živali, vključno s posameznimi primeri)
The MAH must ensure that the system of pharmacovigilance, as described in Part 1 of the marketing authorisation application, is in place and functioning before and whilst the product is on the market. 
• Preostali pogoji Farmakovigilančni sistem Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, kot je opisano v delu 1 vloge za pridobitev dovoljenja za promet z zdravilom, vzpostavljen in delujoč, preden se zdravilo da v promet in med njegovim trženjem.
Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids (oxicams) ATCvet code: QM01AC06 
Farmakoterapevtska skupina: protivnetna in protirevmatična zdravila, nesteroidna (oksikami) Oznaka ATCvet: QM01AC06.
Bimeda Animal Health Limited, 2, 3 & 4 Airton Close, Tallaght, Dublin 24, Ireland. 
Bimeda Animal Health Limited, 2, 3 & 4 Airton Close, Tallaght, Dublin 24, Irska
In cattle, meloxicam is also a major excretion product in milk and bile whereas urine contains only traces of the parent compound. 
Pri govedu je meloksikam tudi pomembna sestavina pri izločanju zdravila z mlekom in žolčem, medtem ko vsebuje urin samo sledi matične spojine.
Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces. 
Približno 50 % prejetega odmerka se izloči s sečem, preostanek pa z blatom.
Vials contain 10 ml, 50 ml or 100 ml. 
Viale vsebujejo 10 ml, 50 ml ali 100 ml zdravila.
MANUFACTURER'S BATCH NUMBER LOT {number} 
PROIZVAJALČEVA ŠTEVILKA SERIJE LOT {številka}
In horses, a transient swelling at the injection site can occur but resolves without intervention. 
Pri konjih se lahko na mestu injiciranja pojavi prehodna oteklina, ki uplahne brez intervencije.
In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention. 
Če pri zdravljenju s koliko povezane bolečine pri konjih ublažitev bolečin ni zadostna, je treba ponovno pazljivo proučiti diagnozo, saj bi to lahko pomenilo, da bo potreben kirurški poseg.
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. 
Meloksikam je nesteroidno protivnetno zdravilo (NSAID) iz skupine oksikamov, ki deluje zaviralno na tvorbo prostaglandinov, pri čemer deluje protivnetno, antieksudativno, analgetično in antipiretično.
Overdose (symptoms, emergency procedures, antidotes): In the case of overdose, symptomatic treatment should be initiated. 
Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi): Pri prevelikem odmerjanju uvedite simptomatsko zdravljenje.
Comparatively low concentrations are detectable in skeletal muscle and fat. 
Razmeroma majhne koncentracije so zaznavne v skeletnih mišicah in maščevju.
Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions. 
Ne uporabljajte pri živalih z motnjami jetrne, srčne ali ledvične funkcije in s hemoragičnimi motnjami ter pri dokazanih ulkusnih lezijah v prebavilih.
In the case of overdose, symptomatic treatment should be initiated. 
Pri prevelikem odmerku uvedemo simptomatsko zdravljenje.
Cattle: SC, IV 
Govedo: s.c., i.v.
Excipient: Ethanol 99.9% 150 mg 
Pomožna snov: Etanol 99,9 % 150 mg Bistra rumena raztopina
150 mg For the full list of excipients, see section 6.1. 
Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
• Conditions or restrictions regarding supply and use imposed on the marketing authorisation holder 
• Pogoji ali omejitve glede oskrbe in uporabe zdravila, predpisani imetniku dovoljenja za promet z zdravilom.
Pack size of 1 Type I clear glass vial with Teflon coated bromobutyl rubber stoppers and sealed with an aluminium flip-off tear-off seal. 
Velikost pakiranja: 1 viala iz brezbarvnega stekla tipa I z brombutilnim gumijastim zamaškom, prevlečenim s teflonom, in odtržno zaporko iz aluminija.
Do not use in cases of hypersensitivity to the active substance or to any of the excipient(s). 
Ne uporabljajte v primerih preobčutljivosti na učinkovino(e) ali na katero koli pomožno snov.
• Conditions or restrictions with regard to the safe and effective use of the medicinal product 
• Pogoji ali omejitve v zvezi z varno in učinkovito uporabo zdravila Ni smiselno.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy. 
Kot dodatna terapija pri zdravljenju puerperalne septikemije in toksemije (sindroma mastitis-metritisagalactia) ob ustreznem antibiotičnem zdravljenju.
Pigs: IM 
Prašiči: i.m.
For use in the alleviation of inflammation and the relief of pain in both acute and chronic musculoskeletal disorders, oral suspensions of meloxicam may be used for continuation of treatment at a dosage of 0.6 mg meloxicam/kg body weight, 24 hours after administration of the injection. 
Za ublažitev vnetja in bolečin pri akutnih in kroničnih mišično-skeletnih obolenjih se lahko uporabi peroralna raztopina meloksikama za nadaljevanje zdravljenja v odmerku 0,6 mg meloksikama/kg telesne mase 24 ur po injiciranju.